Disc Medicine, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock$0.0001 Par Value · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income	Deficit	Equity
Balance at December 31, 2024	29,865,030	$3	$741,297	$289	$(298,002)	$443,587
Issuance of common stock upon exercise of stock options	91,524	—	575	—	—	575
Issuance of common stock upon vesting of restricted stock units	83,672	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	7,814	—	287	—	—	287
Sale of common stock in underwritten offering, net of issuance costs of $15,321	4,533,182	—	234,003	—	—	234,003
Sale of pre-funded warrants in underwritten offering, net of issuance costs of $615	—	—	9,386	—	—	9,386
Stock-based compensation expense	—	—	6,363	—	—	6,363
Foreign currency translation adjustments	—	—	—	14	—	14
Unrealized gain on marketable securities	—	—	—	232	—	232
Net loss	—	—	—	—	(34,085)	(34,085)
Balance at March 31, 2025	34,581,222	$3	$991,911	$535	$(332,087)	$660,362
Issuance of common stock upon exercise of stock options	110,230	—	892	—	—	892
Issuance of common stock upon vesting of restricted stock units	3,430	—	—	—	—	—
Stock-based compensation expense	—	—	8,420	—	—	8,420
Foreign currency translation adjustments	—	—	—	(15)	—	(15)
Unrealized loss on marketable securities	—	—	—	(247)	—	(247)
Net loss	—	—	—	—	(55,247)	(55,247)
Balance at June 30, 2025	34,694,882	$3	$1,001,223	$273	$(387,334)	$614,165
Issuance of common stock upon exercise of stock options	128,482	—	1,531	—	—	1,531
Issuance of common stock upon vesting of restricted stock units	14,514	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	6,301	—	291	—	—	291
Sale of common stock in at-the-market offering,net of issuance costs of $302	162,457	1	9,765	—	—	9,766
Stock-based compensation expense	—	—	9,514	—	—	9,514
Foreign currency translation adjustments	—	—	—	—	—	—
Unrealized gain on marketable securities	—	—	—	445	—	445
Net loss	—	—	—	—	(62,321)	(62,321)
Balance at September 30, 2025	35,006,636	4	1,022,324	718	(449,655)	573,391

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Continued)

Common Stock$0.0001 Par Value · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2023	24,360,233	$2	$533,764	$—	$(188,645)	$345,121
Issuance of common stock upon exercise of stock options	95,467	—	806	—	—	806
Issuance of common stock under employee stock purchase plan	5,736	—	245	—	—	245
Sale of common stock in at-the-market offerings, net of issuance costs of $518	234,449	—	14,790	—	—	14,790
Stock-based compensation expense	—	—	4,058	—	—	4,058
Net loss	—	—	—	—	(26,949)	(26,949)
Balance at March 31, 2024	24,695,885	$2	$553,663	$—	$(215,594)	$338,071
Issuance of common stock upon exercise of stock options	68,112	—	567	—	—	567
Sale of common stock in underwritten offering, net of issuance costs of $5,472	4,944,000	1	172,511	—	—	172,512
Stock-based compensation expense	—	—	4,091	—	—	4,091
Foreign currency translation adjustments	—	—	—	6	—	6
Unrealized loss on marketable securities	—	—	—	(66)	—	(66)
Net loss	—	—	—	—	(26,352)	(26,352)
Balance at June 30, 2024	29,707,997	$3	$730,832	$(60)	$(241,946)	$488,829
Issuance of common stock upon exercise of stock options	34,811	—	401	—	—	401
Issuance of common stock under employee stock purchase plan	5,346	—	196	—	—	196
Stock-based compensation expense	—	—	4,332	—	—	4,332
Foreign currency translation adjustments	—	—	—	(48)	—	(48)
Unrealized gain on marketable securities	—	—	—	849	—	849
Net loss	—	—	—	—	(26,599)	(26,599)
Balance at September 30, 2024	29,748,154	$3	$735,761	$741	$(268,545)	$467,960

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.